Lipid Particle Composition for Bone Marrow Targeting

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current liposome preparations do not effectively target the bone marrow, particularly for panobinostat, a hydroxamic acid derivative used in treating multiple myeloma, lacking high bone marrow-targeting capability.

Innovation Solution

A lipid particle composition containing panobinostat or its salt, comprising a phospholipid and cholesterol, with specific formulations that enhance bone marrow accumulation, including remote loading and controlled particle size and composition to achieve high bone marrow-targeting capability.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If traditional liposome preparations are used, then the drug can be encapsulated and delivered, but the bone marrow-targeting capability is insufficient

Engineering Contradiction:
Improvebone marrow-targeting capabilityVSAvoidtissue distribution specificity
Core Design Contradiction:
ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent modifies the liposome composition by incorporating specific lipids (cholesterol, phosphatidylcholine, sphingomyelin) in optimized ratios, and controls particle size parameters (50-500 nm average diameter) to enhance bone marrow targeting. These parameter changes transform the liposome from a general delivery vehicle to a bone marrow-specific targeting system.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The invention creates a composite liposome structure combining multiple lipid components (cholesterol, phosphatidylcholine, sphingomyelin) with panobinostat drug molecules. This composite material approach enables the liposome to exhibit both drug delivery functionality and bone marrow-specific targeting properties that individual components cannot achieve alone.

Inventive Principle:
Principle #40Composite materials

2Reliability

If the lipid particle composition is optimized for bone marrow targeting, then the therapeutic index is improved, but the formulation complexity increases

Engineering Contradiction:
Improvetherapeutic indexVSAvoidformulation complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent establishes specific parameter ranges for lipid composition (cholesterol 20-50 mol%, phosphatidylcholine 30-60 mol%, sphingomyelin 10-30 mol%) and particle size (50-500 nm) that optimize the therapeutic index. By defining these parameters, the complex formulation process becomes more controllable and reproducible.

Inventive Principle:
Principle #35Parameter changes

Data Source

PatentEP3560492B1Lipid particle composition and pharmaceutical composition
Publication Date: 2023.11.29 FUJIFILM CORP
  • EP3560492B1 patent drawingFigure 1
  • EP3560492B1 patent drawingFigure 2
  • EP3560492B1 patent drawingFigure 3

AI summary

An object of the present invention is to provide a lipid particle composition containing panobinostat or a salt thereof and exhibiting a high bone marrow-targeting capability, and a pharmaceutical composition including the lipid particle composition. According to the present invention, provided is a lipid particle composition containing panobinostat or a salt thereof, in which a lipid particle contains a phospholipid and cholesterol.